Advances in chemotherapy of small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 418-423, 2016.
Article
in Zh
| WPRIM
| ID: wpr-490335
Responsible library:
WPRO
ABSTRACT
Small cell lung cancer (SCLC) accounts for about 13%of lung cancer. SCLC exhibits an early metastatic potential and sensitivi-ty to first-line cytotoxic chemotherapy compared with non-small cell lung cancer. Current treatments include surgery, radiotherapy, and chemotherapy. Platinum plus etoposide is viewed as the standard first-line chemotherapy. However, recurrence rate of cancer af-ter platinum plus etoposide chemotherapy is high. Topotecan monotherapy is the standard second-line chemotherapy. Meanwhile, novel targeted immunotherapy showed poor effects. Hence, new breakthroughs in the treatment of SCLC are urgently needed.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Clinical Oncology
Year:
2016
Type:
Article